Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Trends Mol Med (2017) 23(8):75668
This is a compounded medication prepared by a licensed 503A pharmacy and is not an FDA-approved product
Overall, about one in five (22%) adults who are not currently taking GLP-1 drugs (88% of the public) say they would be interested in taking a GLP-1 drug to lose weight, including just 7% who say they would be very interested. This rises to four in ten (43%) among adults who are not currently taking a GLP-1 but report being diagnosed as overweight or obese in the past five years, and about one in four (27%) among those who say they have been diagnosed with diabetes or heart disease
The FDA had granted Makena approval under a policy meant to incentivize companies to run the costly trials needed to prove that older, unapproved drugs were safe and effective
Glucagon-like peptide-1 (GLP-1) medications, widely known for their effectiveness in promoting weight loss in individuals struggling with obesity and type 2 diabetes, are showing promising new potential benefits beyond metabolic health
Significant or concerning changes in your blood sugar levels
.webp)
